HRES 1125
116th Congress
House
Health
Cardiovascular and respiratory health
Community life and organization
Emergency medical services and trauma care
Health care coverage and access
Health programs administration and funding
Immunology and vaccination
Infectious and parasitic diseases
Medical research
Medical tests and diagnostic methods
Minority health
Research administration and funding
Expressing support for prioritizing racial and ethnic diversity in clinical trials for therapies, diagnostics, and vaccines for COVID-19.
Introduced: September 18, 2020
See on congress.gov
Everywhere this bill has been
2 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Sep 18, 2020
Referred to the House Committee on Energy and Commerce.
Sep 18, 2020
Introduced in House
Plain-English summary
This resolution expresses the sense of the House of Representatives that federal agencies should take appropriate actions to (1) ensure meaningful engagement of communities of color in the conduct of COVID-19 (i.e., coronavirus disease 2019) research and participation in clinical trials, and (2) improve equitable access to safe and effective vaccines.
What's happening now
Referred to the House Committee on Energy and Commerce.
Committees of jurisdiction
1